Liestal, Switzerland, April 4, 2014 - Santhera Pharmaceuticals (SIX: SANN) announced today that Thomas Meier, Chief Executive Officer of Santhera, will present at the upcoming Swiss Biotech Day on Tuesday, April 8, 2014. Mr Meier will provide an update on forthcoming regulatory and development milestones and present the financial results for 2013 and for the first quarter of 2014. The presentation will be available for download on the Company`s website www.santhera.com under Investors/Presentations. In compliance with SIX regulations, the news release and Annual Report will be published on April 8, 2014, at 07:00 CET.
The Swiss Biotech Day is the leading biotechnology conference in Switzerland. Every year, this event brings together more than 200 senior executives from the life science industry across Europe. Program highlights will include the presentation of the Swiss biotech report and key note lectures by renowned industry leaders and scientists. The event is being held at the Kongresshaus, Gotthardtrasse 5, in Zurich, Switzerland.
* * *
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative pharmaceutical products for the treatment of orphan mitochondrial and neuromuscular diseases, such as Leber`s Hereditary Optic Neuropathy, Duchenne Muscular Dystrophy and primary progressive Multiple Sclerosis, all of them areas of high unmet medical need with no current therapies. For further information, please visit the Company`s website www.santhera.com.
For further information, contact
Thomas Meier, Chief Executive Officer
Phone: +41 61 906 89 64
Disclaimer / Forward-looking statements
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Santhera Pharmaceuticals Holding AG via GlobeNewswire